Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 148

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 148
---
 of approximately $74.4 million. Substantially all of its operating losses resulted from costs incurred in connection with its clinical development program and from general and administrative costs associated with its operations. The additional financing investments of approximately $2.5million to be raised prior to the Closing Date is not a condition to Closing; if more or less than $2.5million is raised, the Exchange Ratio will change accordingly pursuant to the terms of the Merger Agreement. NLS expects its research and development expenses to increase in connection with its planned expanded clinical trials. In addition, if NLS obtains marketing approval for Quilience and/or Nolazol, or any other current or future product candidate, NLS will likely incur significant sales, marketing and outsourced manufacturing expenses, as well as continued research and development expenses. Furthermore, NLS expects to incur additional costs associated with operating as a public company, which NLS estimate will be at least several hundred thousand dollars annually. As a result, NLS expects to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, NLS is unable to predict the extent of any future losses or when NLS will become profitable, if at all. NLS expects to continue to incur significant losses until NLS is able to commercialize its product candidates, which NLS may not be successful in achieving. NLS anticipates that its expenses will increase substantially if and as it: •continues the research and development of our product candidates; •expands the scope of our current clinical studies for our product candidates; •seeks regulatory and marketing approvals for our product candidates that successfully complete clinical studies; •establishes a sales, marketing, and distribution infrastructure to commercialize our product candidates; •seeks to identify, assess, acquire, license, and/or develop other product candidates and subsequent generations of our current product candidates; •seeks to maintain, protect, and expand our intellectual property portfolio; •seeks to attract and retain skilled personnel; and •creates additional infrastructure to support our operations as a public company and our product candidate development and planned future commercialization efforts. NLS has not generated revenues from any product candidate and may never be profitable. NLS’s ability to become profitable depends upon its ability to generate revenues. To date, NLS has not generated any revenue from its pre -clinicaland clinical development stage product candidates, Quilience, Nolazol and NLS -4, and NLS does not know